Belite Bio, Inc (BLTE)

NASDAQ: BLTE · IEX Real-Time Price · USD
45.73
-0.42 (-0.92%)
Feb 28, 2024, 2:30 PM EST - Market open
-0.92%
Market Cap 1.29B
Revenue (ttm) n/a
Net Income (ttm) -12.65M
Shares Out 27.60M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 42,835
Open 45.97
Previous Close 46.15
Day's Range 44.00 - 45.97
52-Week Range 11.00 - 48.60
Beta n/a
Analysts Strong Buy
Price Target 48.80 (+6.73%)
Earnings Date Mar 12, 2024

About BLTE

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 16
Stock Exchange NASDAQ
Ticker Symbol BLTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price forecast is $48.8, which is an increase of 6.73% from the latest price.

Price Target
$48.8
(6.73% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...

21 days ago - GlobeNewsWire

Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative ...

3 months ago - GlobeNewsWire

Belite Bio to Participate in the BTIG Ophthalmology Day

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...

3 months ago - GlobeNewsWire

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeu...

3 months ago - GlobeNewsWire

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc  (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative...

4 months ago - GlobeNewsWire

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative ...

4 months ago - GlobeNewsWire

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

SAN DIEGO, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degen...

4 months ago - GlobeNewsWire

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeu...

7 months ago - GlobeNewsWire

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeu...

7 months ago - GlobeNewsWire

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeu...

7 months ago - GlobeNewsWire

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeu...

7 months ago - GlobeNewsWire

Top 5 Health Care Stocks That Are Set To Fly In Q2

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CLPTCOOIRTCSTAA
9 months ago - Benzinga

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel thera...

9 months ago - GlobeNewsWire

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel thera...

9 months ago - GlobeNewsWire

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeut...

10 months ago - GlobeNewsWire

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degene...

10 months ago - GlobeNewsWire

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

The webinar will take place on Wednesday, May 10, 2023 at 1:00 PM ET SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development com...

10 months ago - GlobeNewsWire

Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting

SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics target...

11 months ago - GlobeNewsWire

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

Virtual event on Wednesday, May 3 rd at 1:00 PM ET will feature key opinion leader Hendrik Scholl, M.D. from the University of Basel, Switzerland

11 months ago - GlobeNewsWire

Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a San Diego based clinical stage biopharmaceutical drug development company targeting eye dise...

11 months ago - GlobeNewsWire

Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet ...

11 months ago - GlobeNewsWire

Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, t...

1 year ago - GlobeNewsWire

Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data

“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration”

1 year ago - GlobeNewsWire

Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022

SAN DIEGO, Oct. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, t...

1 year ago - GlobeNewsWire

Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, ...

1 year ago - GlobeNewsWire